PDF   Print   View All
December 18, 2002
Rebroadcast of Hemispherx's December 18, 2002 Conference Call Available On Company's Website or Via Telephone Replay
Philadelphia, PA, Wednesday, December 18, 2002: Hemispherx Biopharma, Inc. (AMEX: HEB), a leading company in the experimental-stage development of immune based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome, announced today that an audio replay of the Company’s conference call on Wednesday, December 18, 2002 at 11:00 AM EST will be available on the Company’s website, www.Hemispherx.net, or via telephone from December 19, 2002 through Friday, January 7, 2003.

During the call, the Company discussed the Data presented by Dr. Gary Blick, Chief Independent Clinical Investigator for the Company’s Phase IIb Trials for HIV/AIDS, at his recent presentation at the 2002 DART Conference in Naples, Florida. Also discussed were the recent developments in the Company’s Phase III trial for Chronic Fatigue Syndrome, its U.S. Government funded trials, and the overall status of the company, including management’s positive outlook on current fundraising activities.

In order to listen to the rebroadcast, please go to www.Hemispherx.net and follow the link, or dial (800) 428 – 6051 or (973) 709 – 2089 for the telephone replay and state the password, which is 272867.

About Hemispherx

Hemispherx Biopharma, Inc is a biopharmaceutical company that focuses on the innovative development of ribonucleic acid (RNA) drug technologies intended to enhance the natural anti-viral defense system of the human body, representing a potential new class of pharmaceutical products. Its primary product, Ampligen, is in two phase IIb clinical trials for HIV/AIDS, one experimental Salvage Therapy and one Strategic Treatment Intervention (STI), and a phase III clinical trial for Chronic Fatigue Syndrome (CFS). For more information, you can visit the corporate website at www.hemispherx.net.

Hemispherx Biopharma, Inc.
(215) 988-0080, Fax (215) 988-1739

Dianne Will, Investor Relations
(518) 398-6222, Fax: (518) 398-6223

Wesley Stanton, MRB Investor Relations,
(212) 495-0200, Fax: (212) 495-0746

Robin Wagge, Rubenstein Associates, Inc.
(212) 843-8006

HEB's Web Site: www.hemispherx.net

Information contained in this news release other than historical information, including the referenced REARM 1 and REARM 2 clinical programs, should all be considered forward-looking and are subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.